Topical Ruxolitinib in Chronic Hand Dermatitis

Part of paid clinical trials in Rochester, New York.

Sponsor: University of Rochester
Study ID: NCT05293717
Phase: PHASE1/PHASE2
Status: Completed

Conditions

Chronic Hand Dermatitis

Eligibility Criteria

Sex: ALL
Age: 18 Years - 75 Years
Healthy Volunteers: Not accepted

Interventions

Ruxolitinib — DRUG
1.5% Ruxolitinib cream

Study Details

This is an investigator-initiated, proof of concept, open study to assess efficacy of a topical Ruxolitinib in subjects with Chronic Hand Dermatitis (CHD). The study will be conducted at the University of Rochester Medical center, Dermatology Department - Rochester, NY. Qualified and enrolled subjects (see Inclusion/Exclusion criteria) will be required to come to URMC Dermatology Clinic for at least five visits.

Key Dates

Start date: Jul 11, 2022
Status verified: Feb 2025
Primary completion: Jun 21, 2023
Completion: Dec 31, 2024

Study Design

Enrollment: 16 participants (actual)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: All Participants
You are being asked to apply topical medication called Ruxolitinib cream to your skin at home twice daily.

Primary Outcome Measure

Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment [ Time Frame: week 12 ]

Locations (1)

Facility	City	State	ZIP	Site coordinators
UR Medicine Dermatology College Town	Rochester	New York	14642	-

Find similar trials in Rochester, NY

By research site

UR Medicine Dermatology College Town· Rochester, NY